Effects of Cataract Surgery after Treatment for Retinoblastoma
Tianwei Liang,Qiyan Li,Songyi Wu,Junyang Zhao
Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China;
Beijing Ophthalmology and Visual Sciences Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;
Department of Ophthalmology, Quanzhou Children's Hospital, Fujian Medical University Teaching Hospital, Quanzhou 362000, China.
Objective: To evaluate the safety and timing of cataract surgery in eyes with retinoblastoma according to the time of diagnosis, treatment, operation method, and operation result. Methods: We reviewed the medical records of 23 patients (25 eyes) who underwent cataract extraction at Beijing Children's Hospital,Beijing Tongren Hospital, and Quanzhou Children's Hospital for a secondary cataract that developed after retinoblastoma treatment. The subjects included 11 boys (11 eyes) and 12 girls (14 eyes). Seven eyes underwent transparent corneal incision with a 25G vitreous cutter, and 18 eyes underwent scleral micro-incision at the flat portion of the ciliary body with either a 25G or 27G vitreous cutter. Follow-up was carried out for 1-72 months, with an average of 24 ± 16 months. The aim of the follow-up was to measure time from cataract diagnosis to operation, to examine the number and types of preoperative treatments, and to observe whether or not there was tumor metastasis around the surgical incision. Results: The average age of the children who participated in the study was 35 ± 19 months (range, 14-72 months). The time (median) from retinoblastoma diagnosis to discovery of a cataract was 19 months, and the time lapse(median) between cataract discovery and cataract surgery was 5 months. The time (median) between the previous retinoblastoma treatment and cataract surgery was 10 months. Before cataract extraction, we carried out 102 systemic chemotherapies on 22 children, 62 local laser treatments on 12 eyes, 19 intravitreal injections on 11 eyes, one radiotherapy on one eye, 10 freezing treatments on 6 eyes, and performed 20 vitrectomies on 17 eyes. In two eyes, the fundus could not be seen during the treatment process. The fundus couldn't be seen in two patients, but there was a recurrence of the tumor by the B ultrasonic examination.The cataracts were surgically removed, and the tumors were postoperatively trented by local laser. There was no recurrence of the tumor in these two patients within the follow-up period. Twenty-three eyes were
operated on after tumor calcification, and 19 of those showed no recurrence within the follow-up period. Late tumor-related complications appeared in four eyes, including one that developed secondary glaucoma,two with hyphemas, and one with a recurrence of the intraocular tumor. In these cases, the eye had to be
enucleated. Pathologic examination revealed no metastasis associated with the cataract surgery incision.Conclusions: For children with retinoblastoma, cataract surgery was necessary to provide a clear field of vision for fundus examination, especially among children who needed to continue retinoblastoma treatment. Cataract surgery is safe when choosing an incision site on the cornea or the flat part of the ciliary body, which minimizes the complexity of the operation in eyes without tumor growth.
梁天蔚,李琦琰,吴松一,赵军阳. 视网膜母细胞瘤并发白内障的手术效果[J]. 中华眼视光学与视觉科学杂志, 2017, 19(10): 613-617.
Tianwei Liang,Qiyan Li,Songyi Wu,Junyang Zhao. Effects of Cataract Surgery after Treatment for Retinoblastoma. Chinese Journal of Optometry Ophthalmology and Visual science, 2017, 19(10): 613-617. DOI: 10.3760/cma.j.issn.1674-845X.2017.10.006
Chawla B, Khurana S, Sen S, et al. Clinical misdiagnosis of retinoblastoma in Indian children. Br J Ophthalmol, 2014, 98(4):488-493. DOI: 10.1136/bjophthalmol-2013-304321.
[3 Villegas VM, Hess DJ, Wildner A, et al. Retinoblastoma.Curr Opin Ophthalmol, 2013, 24(6): 581-588. DOI: 10.1097/ICU.0000000000000002.
[4]
Zhao JY, Li SF, Shi JT, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI:
[1]
魏文斌, 陈积中. 眼底病鉴别诊断学. 北京: 人民卫生出版社,2012: 455-458.
[2]
Chawla B, Khurana S, Sen S, et al. Clinical misdiagnosis of retinoblastoma in Indian children. Br J Ophthalmol, 2014, 98(4):488-493. DOI: 10.1136/bjophthalmol-2013-304321.
[3 Villegas VM, Hess DJ, Wildner A, et al. Retinoblastoma.Curr Opin Ophthalmol, 2013, 24(6): 581-588. DOI: 10.1097/ICU.0000000000000002.
[4]
Zhao JY, Li SF, Shi JT, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI:
10
1136/bjo.2010.191130.
10
1136/bjo.2010.191130.
[5]
Lee V,Hungerford JL,Bunce C,et al. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol, 2003, 87(11): 1374-1380.
[6]
Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol, 2013, 98(3): 292-297. DOI: 10.1136/bjophthalmol-2013-303885.
Kim HM, Lee BJ, Kim JH, et al. Outcomes of cataract surgery following treatment for retinoblastoma. Korean J Ophthalmol,2017, 31(1): 52-57. DOI: 10.3341/kjo.2017.31.1.52.
[10]
Ji XD, Hua PY, Li J, et al. Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China. J Ophthalmol, 2016, 2016:4387286. DOI: 10.1155/2016/4387286.
[11]
Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer, 2006, 47(6): 801-805. DOI: 10.1002/pbc.20606.
[12]
Chantada GL, Doz F, Oriuela M, et al. World diaparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer, 2008, 50(3): 692-694. DOI: 10.1002/pbc.21427.
[13]
Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer,2012, 118(22): 5663-5670. DOI: 10.1002/cncr.27563.
[5]
Lee V,Hungerford JL,Bunce C,et al. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol, 2003, 87(11): 1374-1380.
[6]
Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol, 2013, 98(3): 292-297. DOI: 10.1136/bjophthalmol-2013-303885.
Kim HM, Lee BJ, Kim JH, et al. Outcomes of cataract surgery following treatment for retinoblastoma. Korean J Ophthalmol,2017, 31(1): 52-57. DOI: 10.3341/kjo.2017.31.1.52.
[10]
Ji XD, Hua PY, Li J, et al. Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China. J Ophthalmol, 2016, 2016:4387286. DOI: 10.1155/2016/4387286.
[11]
Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer, 2006, 47(6): 801-805. DOI: 10.1002/pbc.20606.
[12]
Chantada GL, Doz F, Oriuela M, et al. World diaparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer, 2008, 50(3): 692-694. DOI: 10.1002/pbc.21427.
[13]
Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer,2012, 118(22): 5663-5670. DOI: 10.1002/cncr.27563.
[14]
Künkele A, Jurklies C, Wieland R, et al. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Br J Ophthalmol, 2013, 97(10): 1277-83. DOI: 10.1136/bjophthalmol-2013-303452. [15] Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol, 2000, 18(1): 12-17. DOI: 10.1200/JCO.2000.18.1.12.
[16]
Beck MN, Balmer A, Dessing C, et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol, 2000, 18(15): 2881-2887. DOI: 10.1002/smj.285.
Portellos M, Buckley EG. Cataract surgery and intraocular lens implantation in patients with retinoblastoma. Arch Ophthalmol,1998, 116(4): 449-452. DOI: 10.1001/archopht.116.4.449.
[21]
Payne JF, Hutchinson AK, Hubbard GB, et al. Outcomes of cataract surgery following radiation treatment for retinoblastoma. J AAPOS, 2009, 13(5): 454-458, e3. DOI: 10.1016/j.jaapos.2009.06.002.
[22]
Miller DM, Murray TG, Cicciarelli NL, et al. Pars plana lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts in retinoblastoma. Ophthalmology,2005, 112(9): 1620-1624. DOI: 10.1016/j.ophtha.2005.04.017.
[23]
Honavar SG, Shields CL, Shields JA, et al. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol, 2001,119(11): 1613-1621. DOI: 10.1001/archopht.119.11.1613.
[24]
Moshfeghi DM, Wilson MW, Grizzard S, et al. Intraocular sugery after treatment of germline retinoblastoma. Arch Ophthalmol,2005, 123(7): 1008-1012. DOI: 10.1001/archopht.123.7.1008.
[14]
Künkele A, Jurklies C, Wieland R, et al. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Br J Ophthalmol, 2013, 97(10): 1277-83. DOI: 10.1136/bjophthalmol-2013-303452. [15] Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol, 2000, 18(1): 12-17. DOI: 10.1200/JCO.2000.18.1.12.
[16]
Beck MN, Balmer A, Dessing C, et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol, 2000, 18(15): 2881-2887. DOI: 10.1002/smj.285.
Portellos M, Buckley EG. Cataract surgery and intraocular lens implantation in patients with retinoblastoma. Arch Ophthalmol,1998, 116(4): 449-452. DOI: 10.1001/archopht.116.4.449.
[21]
Payne JF, Hutchinson AK, Hubbard GB, et al. Outcomes of cataract surgery following radiation treatment for retinoblastoma. J AAPOS, 2009, 13(5): 454-458, e3. DOI: 10.1016/j.jaapos.2009.06.002.
[22]
Miller DM, Murray TG, Cicciarelli NL, et al. Pars plana lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts in retinoblastoma. Ophthalmology,2005, 112(9): 1620-1624. DOI: 10.1016/j.ophtha.2005.04.017.
[23]
Honavar SG, Shields CL, Shields JA, et al. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol, 2001,119(11): 1613-1621. DOI: 10.1001/archopht.119.11.1613.
[24]
Moshfeghi DM, Wilson MW, Grizzard S, et al. Intraocular sugery after treatment of germline retinoblastoma. Arch Ophthalmol,2005, 123(7): 1008-1012. DOI: 10.1001/archopht.123.7.1008.
[25]
Tartarella MB, Britez-Colombi GF, Motono M, et al.Phacoemulsification and foldable acrylic IOL implantation in children with treated retinoblastoma. Arq Bras Oftalmol, 2012,75(5): 348-351.
[25]
Tartarella MB, Britez-Colombi GF, Motono M, et al.Phacoemulsification and foldable acrylic IOL implantation in children with treated retinoblastoma. Arq Bras Oftalmol, 2012,75(5): 348-351.